Premium
Association of endostatin with mortality in patients with chronic heart failure
Author(s) -
Gouya Ghazaleh,
SillerMatula Jolanta M.,
FritzerSzekeres Monika,
Neuhold Stephanie,
Storka Angela,
Neuhofer Lisa M.,
Clodi Martin,
Hülsmann Martin,
Pacher Richard,
Wolzt Michael
Publication year - 2014
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12197
Subject(s) - endostatin , medicine , prospective cohort study , cohort , heart failure , gastroenterology , angiogenesis , cohort study , proportional hazards model
Background Experimental data imply that in decompensated heart failure ( HF ), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients. Methods In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF . Mortality data were recorded during a median follow‐up of 31 months. Results One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all‐cause mortality [ HR 8·7 (95% CI 2·5–30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT ‐pro BNP were above the calculated cut‐off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [ HR 40·8 (95% CI 4·7–354·6); P = 0·001] compared with values lower than the cut‐offs. Conclusions Serum endostatin concentrations are independently associated with all‐cause mortality. Furthermore, combination of endostatin and NT ‐pro BNP discriminates patients at high risk.